ライフサイエンスコーパス: Kaposi sarcoma

1 ssociated with the endothelial-derived tumor Kaposi sarcoma.

2 metabolic complications, frequently develop Kaposi sarcoma.

3 nd 96.3% (77/80) among control patients with Kaposi sarcoma.

4 Human herpesvirus 8 (HHV-8) causes Kaposi sarcoma.

5 ole for this molecule in the pathogenesis of Kaposi sarcoma.

6 with acquired immune deficiency syndrome and Kaposi sarcoma.

7 ty has been found to exceed the incidence of Kaposi sarcoma.

8 posed as options in the future management of Kaposi sarcoma.

9 emodialysis, and iron) in the development of Kaposi sarcoma.

10 detection predicts the onset and severity of Kaposi sarcoma.

11 olecules are involved in the pathogenesis of Kaposi sarcoma.

12 ing surgery revealed no evidence of residual Kaposi sarcoma.

13 and in endothelial-derived spindle cells of Kaposi sarcoma.

14 posttransplant period, one of whom developed Kaposi sarcoma.

15 therapy for extensive or treatment-resistant Kaposi sarcoma.

16 nd phosphorylated RelA was observed in human Kaposi sarcoma.

17 -OIs were Pneumocystis pneumonia (39.1%) and Kaposi sarcoma (20.1%).

18 without HIV, respectively, were as follows: Kaposi sarcoma, 4.4% and 0.01%; non-Hodgkin lymphoma, 4.

19 e advancement of vascular neoplasms, such as Kaposi sarcoma, a common AIDS-defining malignancy.

20 (KSHV) is an oncogenic DNA virus that causes Kaposi sarcoma and AIDS-related primary effusion lymphom

21 V-seropositive male with extensive maxillary Kaposi sarcoma and associated bilateral alveolar bone er

22 first to demonstrate that Axl is induced in Kaposi sarcoma and Kaposi sarcoma herpesvirus (KSHV) tra

23 gnancies except for specific tumors, such as Kaposi sarcoma and mantle cell lymphoma.

24 ay result in lower expression of TbetaRII in Kaposi sarcoma and multicentric Castleman disease.

25 tive incidence and hazard rate decreased for Kaposi sarcoma and non-Hodgkin lymphoma.

26 application as a new treatment modality for Kaposi sarcoma and other cancers of endothelial origin.

27 genic virus that promotes the development of Kaposi sarcoma and other malignancies that occur in pati

28 erpesvirus, is etiologically associated with Kaposi sarcoma and other rare malignancies.

29 upregulation both in vitro and in vivo, and Kaposi sarcoma and primary effusion lymphoma cells demon

30 K1 protein is expressed in Kaposi sarcoma and primary effusion lymphoma.

31 (KSHV) is linked with all clinical forms of Kaposi sarcoma and several lymphoproliferative disorders

32 -1 RNA viral load to HIV-1+ patients without Kaposi sarcoma (and negative for Kaposisarcoma-associate

33 elated to known infections (eg, anal cancer, Kaposi sarcoma) and others unrelated (eg, melanoma, thyr

34 PTLD, Kaposi sarcoma, and lung and bronchial cancers were incr

35 Nonmelanoma skin cancer, Kaposi sarcoma, and posttransplant lymphoproliferative d

36 rcoma, epithelioid hemangioendothelioma, and Kaposi sarcoma are classified according to the line of d

37 ression microarrays that neoplastic cells of Kaposi sarcoma are closely related to lymphatic endothel

38 Consequently, KSHV-infected tumor cells in Kaposi sarcoma are poorly differentiated endothelial cel

39 ART on Kaposi sarcoma, but some evidence for Kaposi sarcoma as a manifestation of immune reconstituti

40 However, oral Kaposi sarcoma associated with erosion of underlying bon

41 n 6 (IL-6) is an important growth factor for Kaposi sarcoma- associated herpesvirus (KSHV)-associated

42 interleukin-6 (vIL-6), a virokine encoded by Kaposi sarcoma- associated herpesvirus, is an issue of c

43 Kaposi sarcoma-associated (KS-associated) herpesvirus (K

44 homa cells infected by Epstein-Barr virus or Kaposi sarcoma-associated herpes virus (KSHV) are exquis

45 Kaposi sarcoma-associated herpes virus (KSHV) contains a

46 Kaposi sarcoma-associated herpes virus (KSHV) encodes a

47 ng protein (vFLIP), encoded by the oncogenic Kaposi sarcoma-associated herpes virus (KSHV), constitut

48 Human herpes virus 8 (HHV-8) or Kaposi sarcoma-associated herpes virus is the etiologic

49 invariably associated with infection by the Kaposi sarcoma-associated herpesvirus (KSHV or HHV8).

50 que rhadinovirus (RRV) is closely related to Kaposi sarcoma-associated herpesvirus (KSHV) and is asso

51 Kaposi sarcoma is caused by infection of Kaposi sarcoma-associated herpesvirus (KSHV) and is char

52 A-binding domains (DBDs), LANA homologs from Kaposi sarcoma-associated herpesvirus (KSHV) and MHV68 e

53 ion that is transferable to MHV68.IMPORTANCE Kaposi sarcoma-associated herpesvirus (KSHV) and murine

54 s subfamily of gammaherpesviruses, including Kaposi sarcoma-associated herpesvirus (KSHV) and murine

55 In Sub-Saharan Africa, where HIV and the Kaposi sarcoma-associated herpesvirus (KSHV) are endemic

56 Kaposi sarcoma-associated herpesvirus (KSHV) can establi

57 Open reading frame 45 (ORF45) of Kaposi sarcoma-associated herpesvirus (KSHV) causes sust

58 T-cell immunity is important for controlling Kaposi sarcoma-associated herpesvirus (KSHV) diseases su

59 Among 233 children, Kaposi sarcoma-associated herpesvirus (KSHV) DNA was det

60 Kaposi sarcoma-associated herpesvirus (KSHV) encodes 12

61 The K1 gene of Kaposi sarcoma-associated herpesvirus (KSHV) encodes a t

62 n tumor viruses Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV) establish p

63 Kaposi sarcoma-associated herpesvirus (KSHV) has a causa

64 Kaposi sarcoma-associated herpesvirus (KSHV) has been as

65 Kaposi sarcoma-associated herpesvirus (KSHV) has been id

66 The Kaposi sarcoma-associated herpesvirus (KSHV) has been li

67 , a multifunctional protein expressed by the Kaposi sarcoma-associated herpesvirus (KSHV) in latently

68 Kaposi sarcoma-associated herpesvirus (KSHV) infection i

69 Kaposi sarcoma-associated herpesvirus (KSHV) infection i

70 The cellular reservoir for Kaposi sarcoma-associated herpesvirus (KSHV) infection i

71 me studies have inferred that an epidemic of Kaposi sarcoma-associated herpesvirus (KSHV) infection i

72 Recent reports link Kaposi sarcoma-associated herpesvirus (KSHV) infection o

73 To develop an animal model of Kaposi sarcoma-associated herpesvirus (KSHV) infection u

74 e of the JCI, Ganem and colleagues show that Kaposi sarcoma-associated herpesvirus (KSHV) inhibits CD

75 Kaposi sarcoma-associated herpesvirus (KSHV) is a B-lymp

76 Kaposi sarcoma-associated herpesvirus (KSHV) is a human

77 Kaposi sarcoma-associated herpesvirus (KSHV) is a human

78 Kaposi sarcoma-associated herpesvirus (KSHV) is a member

79 ically, the thymidine kinase (TK) encoded by Kaposi sarcoma-associated herpesvirus (KSHV) is an extre

80 Kaposi sarcoma-associated herpesvirus (KSHV) is an oncog

81 Kaposi sarcoma-associated herpesvirus (KSHV) is an oncog

82 Kaposi sarcoma-associated herpesvirus (KSHV) is associat

83 Kaposi sarcoma-associated herpesvirus (KSHV) is consiste

84 Kaposi sarcoma-associated herpesvirus (KSHV) is etiologi

85 Kaposi sarcoma-associated herpesvirus (KSHV) is known to

86 Human herpesvirus 8 (HHV-8)/Kaposi sarcoma-associated herpesvirus (KSHV) is linked t

87 Kaposi sarcoma-associated herpesvirus (KSHV) is linked w

88 Infection with Kaposi sarcoma-associated herpesvirus (KSHV) is now know

89 To assess the role of IL-6 in Kaposi sarcoma-associated herpesvirus (KSHV) latency, KS

90 The Kaposi sarcoma-associated herpesvirus (KSHV) latency-ass

91 ng of genes believed to be essential for the Kaposi sarcoma-associated herpesvirus (KSHV) latent life

92 Kaposi sarcoma-associated herpesvirus (KSHV) ORF57 is a

93 Kaposi sarcoma-associated herpesvirus (KSHV) ORF57 is a

94 There is substantial evidence that Kaposi sarcoma-associated herpesvirus (KSHV) plays an im

95 show that the lytic replication cycle of the Kaposi sarcoma-associated herpesvirus (KSHV) promotes do

96 Kaposi sarcoma-associated herpesvirus (KSHV) stimulates

97 at treatment of cells latently infected with Kaposi sarcoma-associated herpesvirus (KSHV) with glycyr

98 Kaposi sarcoma-associated herpesvirus (KSHV), also known

99 Kaposi sarcoma-associated herpesvirus (KSHV), also known

100 associated with epigenetic modifications of Kaposi sarcoma-associated herpesvirus (KSHV), an oncogen

101 Gammaherpesviruses, including Kaposi sarcoma-associated herpesvirus (KSHV), establish

102 Many viruses, including Kaposi sarcoma-associated herpesvirus (KSHV), have evolv

103 Cellular immune responses to Kaposi sarcoma-associated herpesvirus (KSHV), the etiolo

104 virus (HIV) type 1-infected subjects without Kaposi sarcoma-associated herpesvirus (KSHV)-associated

105 The Kaposi sarcoma-associated herpesvirus (KSHV)-encoded lat

106 We recently identified polymorphisms in Kaposi sarcoma-associated herpesvirus (KSHV)-encoded mic

107 Moreover, Kaposi sarcoma-associated herpesvirus (KSHV)-encoded vir

108 We report that A20 is expressed in Kaposi sarcoma-associated herpesvirus (KSHV)-infected pr

109 a and like Kaposi sarcoma has been linked to Kaposi sarcoma-associated herpesvirus (KSHV).

110 All PELs carry Kaposi sarcoma-associated herpesvirus (KSHV).

111 The seroprevalence of Kaposi sarcoma-associated herpesvirus (KSHV)/human herpe

112 Kaposi sarcoma-associated herpesvirus (KSHV)/human herpe

113 Kaposi sarcoma-associated herpesvirus (KSHV; also known

114 The Kaposi sarcoma-associated herpesvirus (KSHV; or human he

115 V4), cytomegalovirus (HHV5), HHV6, HHV7, and Kaposi sarcoma-associated herpesvirus (termed KSV or HHV

116 ) to infection by a novel human herpesvirus (Kaposi sarcoma-associated herpesvirus [KSHV]) is one of

117 -like inhibitory protein (FLIP) protein from Kaposi sarcoma-associated herpesvirus activates the NF-k

118 hundred percent of PELs carry the genome of Kaposi sarcoma-associated herpesvirus and a majority are

119 The oncogenic gamma-herpesviruses EBV and Kaposi sarcoma-associated herpesvirus are ubiquitous hum

120 an gammaherpesviruses Epstein-Barr virus and Kaposi Sarcoma-associated herpesvirus both contain a gly

121 Kaposi sarcoma-associated herpesvirus GPCR (kGPCR) activ

122 other viruses such as Epstein-Barr virus and Kaposi sarcoma-associated herpesvirus have led to the ge

123 ly that the open reading frame 45 (ORF45) of Kaposi sarcoma-associated herpesvirus interacts with p90

124 sion of the viral interleukin-6 homolog from Kaposi sarcoma-associated herpesvirus is also sufficient

125 Kaposi sarcoma-associated herpesvirus is the causative a

126 We found that Kaposi sarcoma-associated herpesvirus K12-1 miRNA (23 ba

127 tiated blood vascular endothelial cells with Kaposi sarcoma-associated herpesvirus leads to their lym

128 o the sustained activation of ERK and RSK in Kaposi sarcoma-associated herpesvirus lytic replication.

129 lity complex class I in cells expressing the Kaposi sarcoma-associated herpesvirus protein K3, is una

130 Human herpesvirus 8 (HHV-8; Kaposi sarcoma-associated herpesvirus)-specific cytotoxi

131 This family includes Epstein-Barr virus and Kaposi sarcoma-associated herpesvirus, human pathogens a

132 Human herpesvirus 8, also known as Kaposi sarcoma-associated herpesvirus, is etiologically

133 n gamma-2 herpesvirus closely related to the Kaposi sarcoma-associated herpesvirus, replicates lytica

134 and endothelial cells latently infected with Kaposi sarcoma-associated herpesvirus, suggesting that a

135 Kaposi sarcoma-associated herpesvirus-encoded interleuki

136 plasm of lymphatic endothelium infected with Kaposi sarcoma-associated herpesvirus.

137 Little evidence suggests a link with Kaposi sarcoma-associated herpesvirus.

138 uch as HIV, Epstein-Barr virus, malaria, and Kaposi sarcoma-associated herpesvirus.

139 Effects of Ca-SP on Kaposi sarcoma-associated herpesvirus/human herpes virus

140 Ca-SP also inhibited entry of Kaposi sarcoma-associated herpesvirus/human herpes virus

141 Kaposi sarcoma-associated herpesvirus/human herpesvirus

142 We cloned ten miRNAs in the Kaposi sarcoma-associated virus (KSHV or HHV8), nine miR

143 The human gamma herpesviruses, Kaposi sarcoma-associated virus (KSHV) and EBV, are asso

144 ciated herpesvirus (KSHV) has been linked to Kaposi sarcoma, body cavity-based lymphoma, and Castlema

145 virus type 1 (HIV-1) infection and risk for Kaposi sarcoma, but behaviors associated with HHV-8 tran

146 a suggesting a beneficial effect of HAART on Kaposi sarcoma, but some evidence for Kaposi sarcoma as

147 However, in some Kaposi sarcoma cells, KSHV undergoes a productive life c

148 traditional AIDS-defining cancers, including Kaposi sarcoma, cervical cancer, and non-Hodgkin lymphom

149 Classic Kaposi sarcoma (cKS) is an inflammatory tumor caused by

150 Knowledge of the pathophysiology of Kaposi sarcoma continues to expand and influence our the

151 Any declines in the incidence of Kaposi sarcoma do not appear to be caused by a decline i

152 Numerous advances have emerged regarding Kaposi sarcoma during the last year, many of which still

153 how that mTOR inhibitors exert a direct anti-Kaposi sarcoma effect by inhibiting angiogenesis and par

154 rature documents a case of AIDS-related oral Kaposi sarcoma exhibiting severe bilateral erosion of th

155 Human herpesvirus 8, which causes Kaposi sarcoma, expresses the MARCH family ubiquitin lig

156 orably alter the clinical characteristics of Kaposi sarcoma favorably, they seem not to alter the nat

157 the virus promotes tumorigenesis leading to Kaposi sarcoma formation.

158 a new diagnostic tool to help differentiate Kaposi sarcoma from its mimics.

159 Regression of Kaposi sarcoma has been characterized histologically for

160 ppears as an AIDS-defining lymphoma and like Kaposi sarcoma has been linked to Kaposi sarcoma-associa

161 Also, a new staging system for classic Kaposi sarcoma has been proposed.

162 assification system for staging AIDS-related Kaposi sarcoma has been refined.

163 derstanding the pathogenesis of AIDS-related Kaposi sarcoma have occurred in the last decade.

164 Incidence was most elevated for Kaposi sarcoma (hazard ratio [HR], 9.1; 95% confidence i

165 y endothelial transformation mediated by the Kaposi sarcoma herpes virus (KSHV)-encoded G-protein-cou

166 st majority of which are infected with KSHV (Kaposi sarcoma herpes virus, also named HHV-8).

167 Kaposi sarcoma herpesvirus (KSHV) induces transcriptiona

168 tion of miR-30b or miR-30c expression during Kaposi sarcoma herpesvirus (KSHV) infection attenuated v

169 lymphatic endothelial cells (LECs) and that Kaposi sarcoma herpesvirus (KSHV) infects both LECs and

170 latency-associated nuclear antigen (LANA) of Kaposi sarcoma herpesvirus (KSHV) is mainly localized an

171 Kaposi sarcoma herpesvirus (KSHV) is specifically associ

172 Kaposi sarcoma herpesvirus (KSHV) is the cause of Kaposi

173 Kaposi sarcoma herpesvirus (KSHV) is the most common cau

174 emonstrate that RelA/NF-kappaB activation by Kaposi sarcoma herpesvirus (KSHV) latency protein vFLIP

175 PURPOSE OF REVIEW: The discovery of Kaposi sarcoma herpesvirus (KSHV) led to recognition of

176 he transmembrane ubiquitin ligase K5/MIR2 of Kaposi sarcoma herpesvirus (KSHV) mediates internalizati

177 Kaposi sarcoma herpesvirus (KSHV) persists as a latent n

178 sttransplantation human herpesvirus-8 (HHV8)/Kaposi sarcoma herpesvirus (KSHV) primary infection and/

179 te that Axl is induced in Kaposi sarcoma and Kaposi sarcoma herpesvirus (KSHV) transformed endothelia

180 Kaposi sarcoma herpesvirus (KSHV), a human gammaherpesvi

181 Kaposi sarcoma herpesvirus (KSHV)-associated multicentri

182 Kaposi sarcoma herpesvirus (KSHV)-associated multicentri

183 Kaposi sarcoma herpesvirus (KSHV)-associated multicentri

184 Kaposi sarcoma herpesvirus (KSHV)-associated multicentri

185 We show that this pathway is blocked in Kaposi sarcoma herpesvirus (KSHV)-infected primary effus

186 Kaposi sarcoma herpesvirus is found in the monotypic pol

187 Amino acid substitutions in Kaposi sarcoma herpesvirus LANA and prototype foamy viru

188 Peptides studied included segments of Kaposi sarcoma herpesvirus latency-associated nuclear an

189 al interferon regulatory factor 1 (vIRF1), a Kaposi sarcoma herpesvirus protein, destabilizes p53 by

190 We studied the presence of Kaposi sarcoma herpesvirus sequences in cell-free DNA (c

191 by human herpesvirus 8 (HHV8, also known as Kaposi sarcoma herpesvirus).

192 imate herpesviruses, including the oncogenic Kaposi sarcoma herpesvirus, encode cyclin D homologues.

193 ar analysis of the cellular cyclin D and the Kaposi sarcoma herpesvirus-cyclin to delineate the molec

194 Worldwide Kaposi sarcoma herpesvirus/human herpesvirus 8 (HHV8) se

195 revealed 3 distinct HHV-8-related entities: Kaposi sarcoma, HHV-8-associated multicentric Castleman

196 ART and ABV and suggest that AIDS-associated Kaposi sarcoma in children may respond well to HAART wit

197 elines for the most effective treatments for Kaposi sarcoma in SSA.

198 o highlight the challenges faced in treating Kaposi sarcoma in this resource-limited environment.

199 Although AIDS-related oral Kaposi sarcoma is a relatively common finding, erosion o

200 Kaposi sarcoma is caused by infection of Kaposi sarcoma-

201 Kaposi sarcoma is considered a neoplasm of lymphatic end

202 rpesvirus (HHV) 8 infection in regions where Kaposi sarcoma is endemic are not known.

203 The biology of Kaposi sarcoma is poorly understood because the dominant

204 a-associated herpesvirus (KSHV) are endemic, Kaposi sarcoma is the most common cancer overall, but mo

205 Kaposi sarcoma is the most common human herpesvirus 8 (H

206 patients who present with an oral neoplasm, Kaposi sarcoma is the tumor most frequently encountered,

207 virus (KSHV) is specifically associated with Kaposi sarcoma (KS) and 2 B cell lymphoproliferative dis

208 tiological agent for the endothelial-derived Kaposi sarcoma (KS) and also for certain lymphoprolifera

209 Incidence rates for Kaposi sarcoma (KS) and lymphomas were highest in the fi

210 pesvirus 8 (HHV-8) is the causative agent of Kaposi sarcoma (KS) and multicentric Castleman disease (

211 from the blood of patients with AIDS-related Kaposi sarcoma (KS) and primary effusion lymphoma (PEL).

212 In Malawian patients with Kaposi sarcoma (KS) and their relatives, we investigated

213 Ten Kaposi sarcoma (KS) exacerbations and 1 newly diagnosed

214 Kaposi sarcoma (KS) herpesvirus-associated multicentric

215 The burden of Kaposi sarcoma (KS) in human immunodeficiency virus (HIV

216 The high frequency of Kaposi sarcoma (KS) in immunodeficiency states, particul

217 Kaposi sarcoma (KS) incidence has decreased since combin

218 Kaposi sarcoma (KS) is a complication of KS-associated h

219 Kaposi sarcoma (KS) is a multifocal angioproliferative n

220 Kaposi sarcoma (KS) is an angioproliferative tumor deriv

221 Kaposi sarcoma (KS) is associated with human herpesvirus

222 Kaposi sarcoma (KS) is associated with KS-associated her

223 Classic Kaposi sarcoma (KS) is exceedingly rare in children from

224 Kaposi sarcoma (KS) is primarily caused by human herpesv

225 Kaposi sarcoma (KS) is the most common AIDS-associated m

226 neovascularization and to the development of Kaposi sarcoma (KS) lesions.

227 Kaposi sarcoma (KS) remains a frequent cancer in human i

228 Kaposi sarcoma (KS) remains the most common AIDS-associa

229 Thirty-six patients with AIDS-associated Kaposi sarcoma (KS) requiring chemotherapy were treated

230 We compared Kaposi sarcoma (KS) risk in adults who started antiretro

231 Kaposi sarcoma (KS) risk is affected by perturbed immuni

232 d clinical manifestations notably range from Kaposi sarcoma (KS) to either primary effusion lymphoma

233 The linkage of Kaposi sarcoma (KS) to infection by a novel human herpes

234 n, angiogenesis, and inflammation to promote Kaposi sarcoma (KS) tumor growth, which involves various

235 HIV-1+ patients with Kaposi sarcoma (KS) were matched for CD4 count and HIV-1

236 red immunodeficiency syndrome (AIDS)-related Kaposi sarcoma (KS) whose KS was progressing while on an

237 Curative treatment of aggressive Kaposi sarcoma (KS) with conventional chemotherapy in hu

238 Kaposi sarcoma (KS), a human herpes virus 8 (HHV-8; also

239 Kaposi sarcoma (KS), a multifocal neoplasm of the skin t

240 erpesvirus (KSHV) is etiologically linked to Kaposi sarcoma (KS), a tumor genetically akin to lymphat

241 rus and the culprit behind the human disease Kaposi sarcoma (KS), an AIDS-defining malignancy.

242 man herpesvirus 8, is the etiologic agent of Kaposi sarcoma (KS), an angioproliferative lesion charac

243 ed in primary effusion lymphoma (PEL) and in Kaposi sarcoma (KS), an endothelial cell tumor.

244 ecimens of 11 HIV-related, 7 non-HIV-related Kaposi sarcoma (KS), and 7 normal skin tissues (NSTs) of

245 k of AIDS-defining malignancies that include Kaposi sarcoma (KS), certain non-Hodgkin lymphomas (NHLs

246 herpesvirus (KSHV) is the causative agent of Kaposi sarcoma (KS), one of the leading cancers in human

247 ical agent of three different human cancers, Kaposi sarcoma (KS), primary effusion lymphoma (PEL) and

248 s of the microRNA-coding region of KSHV from Kaposi sarcoma (KS), primary effusion lymphoma (PEL), an

249 us 8 (KSHV/HHV-8) is etiologically linked to Kaposi sarcoma (KS), primary effusion lymphoma (PEL), an

250 i sarcoma herpesvirus (KSHV) is the cause of Kaposi sarcoma (KS), primary effusion lymphoma (PEL), an

251 virus (HIV)-related and -unrelated cases of Kaposi sarcoma (KS), primary effusion lymphoma (PEL), an

252 erpesvirus (KSHV) is the causative agent for Kaposi sarcoma (KS), primary effusion lymphoma (PEL), an

253 ociated with 3 different human malignancies: Kaposi sarcoma (KS), primary effusion lymphoma, and mult

254 Kaposi sarcoma (KS), the most common neoplasm in patient

255 eukin-6 (vIL-6) has been detected in certain Kaposi sarcoma (KS)--associated herpesvirus positive (KS

256 Kaposi sarcoma (KS)-associated herpesvirus (KSHV) encode

257 lovir, a drug with in vitro activity against Kaposi sarcoma (KS)-associated herpesvirus (KSHV), in cl

258 (CDV), a drug with in vitro activity against Kaposi sarcoma (KS)-associated herpesvirus (KSHV), in KS

259 Antibody responses against lytic and latent Kaposi sarcoma (KS)-associated herpesvirus antigens were

260 Epidemiological studies of Kaposi sarcoma (KS)-related herpesvirus (KSHV) indicate

261 infection is essential to the development of Kaposi sarcoma (KS).

262 as been identified as the etiologic agent of Kaposi sarcoma (KS).

263 svirus-8 (HHV-8) is causally associated with Kaposi sarcoma (KS).

264 ant role in the pathogenesis of all forms of Kaposi sarcoma (KS).

265 a (PCP, 28%), Candida esophagitis (23%), and Kaposi sarcoma (KS, 16%).

266 idence of the 3 AIDS-defining cancers (ADCs; Kaposi sarcoma [KS], non-Hodgkin lymphoma [NHL], and cer

267 Kaposi sarcoma lesional cells, now confirmed to be of ly

268 ate expression of the KSHV-encoded miRNAs in Kaposi sarcoma lesions and demonstrate that these miRNAs

269 The detection of HHV8 in Kaposi sarcoma lesions has provided a new diagnostic too

270 In the transplant setting, Kaposi sarcoma lesions have been shown to originate from

271 understood because the dominant cell type in Kaposi sarcoma lesions is not known.

272 n KSHV-infected spindle tumor cells in human Kaposi sarcoma lesions.

273 n expression was drastically up-regulated in Kaposi sarcoma-like lesions and that loss of IKKepsilon

274 gh cumulative incidences by age 75 years for Kaposi sarcoma, non-Hodgkin lymphoma, and lung cancer su

275 ce of first posttransplant SCC, melanoma, or Kaposi sarcoma of the skin.

276 ases such as the endothelial cell malignancy Kaposi sarcoma, or the B-cell malignancy, primary effusi

277 Kaposi sarcoma originates from endothelial cells and it

278 Advances in Kaposi sarcoma pathophysiology are leading to new therap

279 e tumor cells of endemic and AIDS-associated Kaposi sarcoma, primary effusion lymphoma, and Castleman

280 esvirus 8, is the etiologic agent underlying Kaposi sarcoma, primary effusion lymphoma, and multicent

281 iated herpes virus is the etiologic agent of Kaposi sarcoma, primary effusion lymphoma, and plasma ce

282 critical in the induction and maintenance of Kaposi sarcoma, primary effusion lymphoma, and some case

283 ata show that the gene expression profile of Kaposi sarcoma resembles that of LECs, that KSHV induces

284 transfected BJAB lymphoma, THP-1, U937, and Kaposi sarcoma SLK cells to express K1 and a K1 mutant w

285 the epidemiology, biology, and management of Kaposi sarcoma that was published in the last year.

286 Unlike Kaposi sarcoma, the incidence does not correlate with CD

287 Kaposi sarcoma, the most common cancer in HIV-positive i

288 d literature on treatment of AIDS-associated Kaposi sarcoma, the most common HIV-associated malignanc

289 de prognostic information about AIDS-related Kaposi sarcoma, the traditional classification system fo

290 here are few prospective clinical trials for Kaposi sarcoma treatment in SSA, along with a relatively

291 ssion of lymphatic lineage-specific genes by Kaposi sarcoma tumor cells.

292 hatic microenvironment is more favorable for Kaposi sarcoma tumorigenesis.

293 Thus, Kaposi sarcoma tumors express numerous lymphatic endothe

294 High expression of EZH2 was observed in Kaposi sarcoma tumors.

295 lls and may contribute to the development of Kaposi sarcoma tumors.

296 Kaposi sarcoma was observed in 9 cases.

297 RECENT FINDINGS: A total of 176 non-Kaposi sarcoma were identified, 75 in people with HIV an

298 sive or treatment-refractory AIDS-associated Kaposi sarcoma were treated with peginterferon alfa-2a.

299 rt the development of a novel mouse model of Kaposi sarcoma, where KSHV is retained stably and tumors

300 Kaposi sarcoma, which has reached epidemic proportions i